Anixa Biosciences (NASDAQ:ANIX – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02, Zacks reports.
Anixa Biosciences Price Performance
Shares of NASDAQ ANIX opened at $2.25 on Friday. The company has a market cap of $72.40 million, a PE ratio of -5.77 and a beta of 0.90. The stock has a fifty day moving average price of $2.94 and a 200 day moving average price of $3.02. Anixa Biosciences has a 1-year low of $2.14 and a 1-year high of $5.13.
Analyst Ratings Changes
A number of brokerages have recently issued reports on ANIX. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, November 19th.
About Anixa Biosciences
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Further Reading
- Five stocks we like better than Anixa Biosciences
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Consumer Staples Stocks, Explained
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What Are Growth Stocks and Investing in Them
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
